Kaposi's Sarcoma Kaposi's sarcoma, or KS, is a type of cancer that men with advanced HIV infection may develop. It is rarely seen in women. Although KS mainly affects the skin, the mouth, and the lymph nodes, it can also involve the bowels and lungs. If it becomes severe, it may lead to swelling or breakdown of the skin. Recent studies have shown that KS is caused by a sexually transmitted herpes virus, previously known as KSHV (Kaposi's sarcoma-associated herpes virus), it is now commonly called HHV-8 (human herpes virus 8). Signs and Symptoms
Diagnosis Lungs - When KS is suspected to involve the lungs, a test called a bronchoscopy is usually performed. Xrays and scans can also be used to detect lesions in the lungs. Gastrointestinal tract - KS involving the gastrointestinal tract is best diagnosed with a test called an endoscopy (a flexible fibre optic tube is passed into the intestines through the mouth, to allow the
doctors to see inside). KS and Highly Active Anti-Retroviral Therapy (HAART) Treatment
KS on the skin is not in itself life threatening, and may resolve with HAART. This is the first live treatment. You may decide to have an anti-cancer drug called vinblastine, injected directly into lesions that have not resolved. Larger lesions can also be treated with radiotherapy. If the KS has spread more widely, HAART may be sufficient or chemotherapy may be necessary as well. Liposome drugs can be used for the treatment of KS. Liposome drugs are standard chemotherapy drugs used to treat KS that are put inside microscopic bubbles of fat called liposomes. When the drugs are used this way, it is hoped they have fewer side effects and can be more effective. Two liposomal drugs used are called Doxil and DaunoXome. These drugs are the standard first-line chemotherapy for KS. Chemotherapy is usually given by intravenous infusion as an outpatient every 2-3 weeks for 4 months. It may be necessary to give further courses of chemotherapy if the KS recurs. Side Effects KS can be treated with radiation, chemotherapy and certain immunomodulators. These treatments often have severe toxic side effects such as suppression of bone marrow activity and white blood cell production. Additional side effects, such as hair loss and nausea, may affect quality of life during treatment. New liposomal therapies seem to have less of these side effects. Additional treatments for KS may be necessary if it fails to respond to liposomal anthracyclines (drugs such as Doxil and DaunoXome) and in these circumstances, individually tailored therapy will be offered. Patients with KS may be offered enrolment into clinical trials of new agents.
|

